Welcome to our dedicated page for Neumora Therapeutics news (Ticker: NMRA), a resource for investors and traders seeking the latest updates and insights on Neumora Therapeutics stock.
Neumora Therapeutics Inc (NMRA) is a clinical-stage biopharmaceutical company advancing novel treatments for brain diseases through precision neuroscience. This page serves as the definitive source for NMRA-related news, offering investors and stakeholders timely updates on clinical developments, regulatory milestones, and strategic initiatives.
Access curated press releases and analysis covering key aspects of Neumora's operations, including progress reports on its depression therapy navacaprant (KOR antagonist), Alzheimer's agitation candidate NMRA-511 (V1aR antagonist), and preclinical M4 PAM programs. Our repository simplifies tracking of trial phases, partnership announcements, and scientific publications.
All content undergoes rigorous verification to ensure alignment with financial disclosure standards. Bookmark this page for efficient monitoring of NMRA's innovative work in neuropsychiatric and neurodegenerative disorder treatments. Check regularly for updates on pipeline advancements and corporate announcements that may impact research trajectories.
Neumora Therapeutics (NASDAQ: NMRA) reported Q2 2025 financial results and provided significant pipeline updates. The company ended Q2 with $217.6 million in cash, expected to fund operations into 2027. Key developments include initiating a Phase 1 SAD/MAD study for NMRA-861 in schizophrenia and prioritizing obesity as the lead indication for NMRA-215, their brain-penetrant NLRP3 inhibitor.
Financial results showed R&D expenses of $38.7 million (down from $48.6M in Q2 2024) and a net loss of $52.7 million (improved from $58.7M). The company anticipates six clinical data readouts over the next 18 months, including Phase 3 data for navacaprant in major depressive disorder and Phase 1b data for NMRA-511 in Alzheimer's disease agitation.
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company focused on brain disease treatments, will host its Q2 2025 earnings call on August 6, 2025 at 4:30 p.m. ET. The company, which maintains a pipeline of seven brain disease programs including three in clinical stages, will present financial results and provide a business update.
The event will be accessible via webcast through the company's website at www.neumoratx.com, with a replay available for 30 days post-event. Participants are encouraged to register for the conference call at least 10 minutes before the start time.
Neumora Therapeutics (Nasdaq: NMRA) has initiated a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study of NMRA-861, a highly potent and selective M4 positive allosteric modulator (PAM), in healthy adults and those with stable schizophrenia.
The drug candidate demonstrates potential best-in-class pharmacology and showed promising safety in pre-clinical studies with no convulsions observed across multiple species. The company expects to report Phase 1 data, including safety, tolerability, and pharmacokinetic results, in Q1 2026.
NMRA-861 aims to offer a differentiated treatment option for schizophrenia and other neuropsychiatric disorders, potentially providing improved therapeutic benefits compared to current antipsychotics and non-selective muscarinic agonists, with the possibility of once-daily dosing.
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company, has announced it will host a conference call and live webcast to discuss its first quarter 2025 financial results on Monday, May 12, 2025, at 4:30 p.m. ET.
The company, which maintains a pipeline of seven brain disease programs including two clinical-stage programs, will also provide a business update during the call. Interested participants can access the webcast through the events and presentations section of Neumora's website, with a replay available for up to 30 days after the event.
Neumora Therapeutics (Nasdaq: NMRA), a clinical-stage biopharmaceutical company focused on brain disease treatments, has announced its upcoming presentation at the Leerink Global Healthcare Conference. The presentation is scheduled for Tuesday, March 11, 2025, at 10:00 a.m. ET in Miami, FL.
The company, which maintains a pipeline of seven clinical and pre-clinical brain disease programs, will make the presentation available via live webcast on their website's Events and Presentations section at www.neumoratx.com. The recording will remain accessible for up to 30 days following the event.
Neumora Therapeutics (NMRA) has reported its Q4 and full year 2024 financial results, highlighting key developments in its neuroscience pipeline. The company ended 2024 with $307.6 million in cash and equivalents, expected to fund operations into mid-2026.
Following analysis of KOASTAL-1 results, Neumora has optimized its KOASTAL-2 and -3 studies for major depressive disorder treatment, with topline data expected in Q1 and Q2 2026 respectively. The company has paused and plans to resume these studies in March 2025 with enhanced site selection and medical monitoring.
Key financial metrics for 2024 include R&D expenses of $200.9 million (up from $142.7 million in 2023) and G&A expenses of $62.5 million (up from $45.5 million). The company reported a net loss of $243.8 million for the full year 2024.
Neumora Therapeutics (NASDAQ: NMRA) announced significant leadership changes effective February 14, 2025. Paul L. Berns, co-founder and executive chair, will become CEO and chairman of the Board, replacing Henry Gosebruch. Joshua Pinto, Ph.D., will serve as president, Bill Aurora, Pharm.D., as chief operating and development officer, and Michael Milligan as chief financial officer.
The clinical-stage biopharmaceutical company has seven clinical and pre-clinical brain disease programs in its pipeline, with clinical data readouts expected from all three clinical-stage programs in 2025. A key highlight is the ongoing Phase 3 program with navacaprant in depression. The company focuses on developing novel treatments for brain diseases with therapeutically relevant targets and best-in-class pharmacology.
Neumora will host a conference call on March 3, 2025, to report Q4 and full-year 2024 financial results and provide a business update.
Neumora Therapeutics (NASDAQ: NMRA) announced disappointing results from its Phase 3 KOASTAL-1 Study of navacaprant for major depressive disorder (MDD). The study failed to meet its primary endpoint, showing no statistically significant improvement in depressive symptoms compared to placebo as measured by MADRS total score at Week 6.
Key findings from the 383-patient study include:
- No significant difference between navacaprant and placebo in the overall population
- An efficacy signal observed in female participants (-14.0 vs -11.4 placebo)
- The drug was generally well-tolerated with no serious adverse events
The company reported $342 million cash balance as of Q3, providing runway into mid-2026. Two additional Phase 3 studies (KOASTAL-2 and KOASTAL-3) and a long-term study (KOASTAL-LT) are ongoing.
Neumora Therapeutics (NMRA) reported Q3 2024 financial results with a net loss of $72.5 million, compared to $53.0 million in Q3 2023. R&D expenses increased to $60.6 million from $41.6 million year-over-year. The company maintains a strong financial position with $341.3 million in cash and equivalents, expected to fund operations into mid-2026.
Key pipeline updates include expected Phase 3 KOASTAL-1 study data for navacaprant in major depressive disorder (MDD) by end of 2024, with KOASTAL-2 and KOASTAL-3 results anticipated in H1 2025. Additional studies include Phase 2 trials for bipolar depression and Phase 1b study of NMRA-511 for Alzheimer's disease agitation, both with data expected in H2 2025.
FAQ
What is the current stock price of Neumora Therapeutics (NMRA)?
What is the market cap of Neumora Therapeutics (NMRA)?
